ClinicalTrials.gg
CompletedNCT04722887Updated Oct 8, 2026Results posted

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

A Phase 1/2 interventional study of Alpha-1 15% and Liquid Alpha1-Proteinase Inhibitor (Human) in Alpha1-Antitrypsin Deficiency, sponsored by Grifols Therapeutics LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 1/2, Interventional, and Treatment

Updated Oct 8, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in alpha 1-Antitrypsin Deficiency by Grifols — 2 open to participants now, 2 under way, 2 of them phase 3. alpha 1-Antitrypsin Deficiency · Grifols.

Enrollment
10th of 12
17 · median 34
Started
2021
the only one that year
Phase 1/2
3 of 12
none open now
Registered
11th of 12
by date

Among the 12 studies in alpha 1-Antitrypsin Deficiency by Grifols, this one is the 10th largest by enrollment, is the only one that started in 2021, is one of 3 in phase 1/2, and was the 11th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

2 of the 12 studies in alpha 1-Antitrypsin Deficiency by Grifols are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in alpha 1-Antitrypsin Deficiency by Grifols, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in participants with Alpha1-Antitrypsin Deficiency (AATD).

03

Conditions studied

  • Alpha1-Antitrypsin Deficiency

Keywords

  • Pulmonary Emphysema
  • Alpha-1 Antitrypsin Deficiency
  • AATD
  • Alpha-1 PI Deficiency
  • Alpha-1 Proteinase Inhibitor
  • Emphysema
  • Pathologic Processes
  • Pulmonary Disease, Chronic Obstructive
  • Lung Diseases, Obstructive
  • Lung Diseases
  • Respiratory Tract Diseases
  • Liver Diseases
  • Digestive System Diseases
  • Genetic Diseases, Inborn
  • Subcutaneous Emphysema
  • Alpha1-Antitrypsin
  • Trypsin Inhibitors
  • Serine Proteinase Inhibitors
  • Protease Inhibitors
  • Enzyme Inhibition
  • Molecular Mechanisms of Pharmacological Action
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Have a diagnosis of congenital Alpha1-antitrypsin deficiency (AATD) with an allelic combination of ZZ, SZ, Z(null), (null)(null), S(null), or "at-risk" alleles (subjects with "at-risk" alleles must be individually evaluated for eligibility by the Medical Monitor).
  • Have a documented pre-Alpha1-Proteinase Inhibitor (PI) augmentation therapy serum alpha-1 antitrypsin (AAT) level \<11 micromolar (μM) (80 milligrams per decilitre (mg/dL) if measured by radial immunodiffusion or 50 mg/dL if measured by nephelometry).
  • Subjects may be naïve to Alpha1-PI augmentation therapy or may be currently receiving Alpha1-PI augmentation therapy or received Alpha1-PI augmentation therapy within the past. If the subject is currently receiving Alpha1-PI augmentation therapy of any kind, he/she must be willing to discontinue that treatment for at least 25 days prior to the Week 1 (Baseline) Visit and remain off any kind of Alpha1-PI treatment, other than the IPs for this study, while participating in the study.
  • At the Screening Visit, have a post-bronchodilator (FEV1) ≥30% and \<80% of predicted and FEV1/forced vital capacity (FVC) \<70% (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II or III).

Main Exclusion Criteria:

  • Have had a moderate or severe (COPD) exacerbation during the 4 weeks before the Week 1 (Baseline) Visit.
  • Have history of lung or liver transplant.
  • Have any lung surgery during the past 2 years (excluding lung ).
  • Have severe concomitant disease (example, congestive heart failure, pulmonary fibrosis, malignant disease [except for skin cancers other than melanoma], history of acute pneumonitis reaction, or current chronic hypersensitivity pneumonitis).
  • Females who are pregnant, breastfeeding or, if of , unwilling to practice a highly effective method of (oral, injectable, or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or true abstinence) throughout the study.
  • Have smoked during the past 6 months or a positive urine cotinine test at the Screening Visit that is due to smoking.
  • Participate in another product (IP) study within one month prior to the Week 1 (Baseline) Visit.
  • Have history of anaphylaxis or severe systemic response to any plasma-derived Alpha1-PI preparation or other blood product(s).
  • Use systemic above a stable dose equivalent to 5 mg/day prednisone (i.e., 10 mg every 2 days) within the 4 weeks prior to the Week 1 (Baseline) Visit. It is recommended to maintain the same dose throughout the study.
  • Use systemic or aerosolized antibiotics for a chronic COPD exacerbation within the 4 weeks prior to the Week 1 (Baseline) Visit.
  • Have known selective or severe Immunoglobulin A (IgA) deficiency.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)

    Participants will receive Alpha-1 15% 72 mg/kg, single subcutaneous (SC) infusion in treatment-period 1 (Single-Dose) at Week 1.

    Biological: Alpha-1 15%

  • Experimental
    Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)

    Following the week-long treatment period 1, participants in Cohort 1 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation period. During the single-dose data evaluation period, Liquid Alpha1- Proteinase Inhibitor (PI) 60 mg/kg, weekly intravenous (IV) Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 78, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.

    Biological: Liquid Alpha1-Proteinase Inhibitor (Human)

  • Experimental
    Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)

    Following treatment period 1 and single-dose data evaluation period, participants in Cohort 1 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 72 mg/kg, for 8 weekly SC infusions.

    Biological: Alpha-1 15%

  • Experimental
    Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)

    Participants will receive Alpha-1 15% 180 mg/kg, single SC infusion in treatment-period 1 (Single-Dose) at Week 1.

    Biological: Alpha-1 15%

  • Experimental
    Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)

    Following the week-long treatment period 1, participants in Cohort 2 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation period. During the single-dose data evaluation period, Liquid Alpha1-PI 120 mg/kg, weekly IV Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 78, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.

    Biological: Liquid Alpha1-Proteinase Inhibitor (Human)

  • Experimental
    Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)

    Following treatment period 1 and single-dose data evaluation period, participants in Cohort 2 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 180 mg/kg, for 8 weekly SC infusions.

    Biological: Alpha-1 15%

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    AE that occurred at any time from the beginning of IP administration until the final visit of the clinical trial was considered TEAE.

    Time frame: Up to 668 days

  2. Number of Participants With Suspected Adverse Drug Reactions (ADRs)

    All noxious and unintended responses to a medicinal product or study treatment related to any dose was considered suspected ADRs. The phrase "responses to a medicinal product" means that a causal relationship between a medicinal product or study treatment and an AE is at least a reasonable possibility.

    Time frame: Up to 668 days

  3. Number of Participants With Infusion Site Reactions (ISRs)

    Treatment-emergent ISRs have onset on or after date of the first administration of study treatment up to on or before 28 days after last administration of study treatment. An ISR was counted in the period during which it started.

    Time frame: Up to 668 days

  4. Number of Participants With Serious Adverse Events (SAEs)

    An adverse event is considered serious if, in the judgment of the investigator or sponsor, it results in death, is life-threatening, requires hospitalization or prolongs an existing hospitalization (admission for 24 hours or more, including emergency room stays), causes significant or persistent disability, results in a congenital anomaly or birth defect, or is an important medical event that may jeopardize the subject or require intervention to prevent these outcomes.

    Time frame: Up to 668 days

  5. Number of Participants With Any TEAE Leading to Study Withdrawal

    TEAE Leading to Study Withdrawal refers to a TEAE that results in a participant permanently discontinuing or withdrawing from a clinical study because of the adverse event.

    Time frame: Up to 668 days

  6. Number of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

    The definition of an exacerbation of COPD is an increase in respiratory symptoms (dyspnea, increased cough, and/or production of sputum) over baseline that usually requires medical intervention.

    Time frame: Up to 668 days

  7. Number of Participants With Any Adverse Events Associated With Abnormalities in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate, and Temperature)

    Clinically significant vital sign abnormalities were presented as adverse events, with clinical relevance based on the Investigator's judgment.

    Time frame: Up to 668 days

  8. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

    FEV1 was performed according to ATS/ERS guidelines. At each visit, testing was performed both pre- and post-bronchodilator (BD) administration.

    Time frame: Single-Dose Week 5/Intravenous Week 1, and Repeat-Dose Weeks 1, 4, and 9

  9. Change From Baseline in Forced Vital Capacity (FVC)

    FVC was performed according to ATS/ERS guidelines. At each visit, testing was performed both pre- and post-bronchodilator (BD) administration.

    Time frame: Single-Dose Week 5/Intravenous Week 1, and Repeat-Dose Weeks 1, 4, and 9

  10. Number of Participants With Any Adverse Events Associated With Abnormalities in Laboratory Parameters (Chemistry, Hematology, Urinalysis)

    Out of the normal range laboratory results judged by the Investigator as clinically significant in the context of the participant's medical history were considered adverse events.

    Time frame: Up to 668 days

  11. Immunogenicity: Number of Participants With Alpha1-PI Antibodies

    Immunogenicity testing was performed using validated assays in a multi-tiered approach.

    Time frame: Treatment Period 1- Single-Dose Week 1; Treatment Period 2- Repeat-Dose Weeks 1 and 9

07

Results

Posted Oct 8, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2
Started98
Completed56
Not completed42

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

AE that occurred at any time from the beginning of IP administration until the final visit of the clinical trial was considered TEAE.

Time frame:
Up to 668 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsCohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)573374
PrimaryNumber of Participants With Suspected Adverse Drug Reactions (ADRs)

All noxious and unintended responses to a medicinal product or study treatment related to any dose was considered suspected ADRs. The phrase "responses to a medicinal product" means that a causal relationship between a medicinal product or study treatment and an AE is at least a reasonable possibility.

Time frame:
Up to 668 days
Reported as:
Count of participants · Participants
Number of Participants With Suspected Adverse Drug Reactions (ADRs)
ParticipantsCohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)
Number of Participants With Suspected Adverse Drug Reactions (ADRs)321223
PrimaryNumber of Participants With Infusion Site Reactions (ISRs)

Treatment-emergent ISRs have onset on or after date of the first administration of study treatment up to on or before 28 days after last administration of study treatment. An ISR was counted in the period during which it started.

Time frame:
Up to 668 days
Reported as:
Count of participants · Participants
Number of Participants With Infusion Site Reactions (ISRs)
ParticipantsCohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)
Number of Participants With Infusion Site Reactions (ISRs)301202
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

An adverse event is considered serious if, in the judgment of the investigator or sponsor, it results in death, is life-threatening, requires hospitalization or prolongs an existing hospitalization (admission for 24 hours or more, including emergency room stays), causes significant or persistent disability, results in a congenital anomaly or birth defect, or is an important medical event that may jeopardize the subject or require intervention to prevent these outcomes.

Time frame:
Up to 668 days
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsCohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)
Number of Participants With Serious Adverse Events (SAEs)001021
PrimaryNumber of Participants With Any TEAE Leading to Study Withdrawal

TEAE Leading to Study Withdrawal refers to a TEAE that results in a participant permanently discontinuing or withdrawing from a clinical study because of the adverse event.

Time frame:
Up to 668 days
Reported as:
Count of participants · Participants
Number of Participants With Any TEAE Leading to Study Withdrawal
ParticipantsCohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)
Number of Participants With Any TEAE Leading to Study Withdrawal111001
PrimaryNumber of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

The definition of an exacerbation of COPD is an increase in respiratory symptoms (dyspnea, increased cough, and/or production of sputum) over baseline that usually requires medical intervention.

Time frame:
Up to 668 days
Reported as:
Count of participants · Participants
Number of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
ParticipantsCohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)
Number of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations122021
PrimaryNumber of Participants With Any Adverse Events Associated With Abnormalities in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate, and Temperature)

Clinically significant vital sign abnormalities were presented as adverse events, with clinical relevance based on the Investigator's judgment.

Time frame:
Up to 668 days
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Events Associated With Abnormalities in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate, and Temperature)
ParticipantsCohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)
Number of Participants With Any Adverse Events Associated With Abnormalities in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate, and Temperature)010010
PrimaryChange From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

FEV1 was performed according to ATS/ERS guidelines. At each visit, testing was performed both pre- and post-bronchodilator (BD) administration.

Time frame:
Single-Dose Week 5/Intravenous Week 1, and Repeat-Dose Weeks 1, 4, and 9
Reported as:
Mean · litres
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
litresCohort 1Cohort 2
Pre-BD - IV Week 1-0.093 ± 0.1381-0.016 ± 0.1098
Pre-BD - RD Week 1-0.033 ± 0.1532-0.029 ± 0.1160
Pre-BD - RD Week 40.110 ± 0.31070.006 ± 0.1477
Pre-BD - RD Week 90.080 ± 0.11380.013 ± 0.1473
Post-BD - IV Week 1-0.031 ± 0.13910.004 ± 0.0737
Post-BD - RD Week 1-0.058 ± 0.0917-0.034 ± 0.0998
Post-BD - RD Week 40.104 ± 0.19370.016 ± 0.1332
Post-BD - RD Week 90.158 ± 0.30880.053 ± 0.0900
PrimaryChange From Baseline in Forced Vital Capacity (FVC)

FVC was performed according to ATS/ERS guidelines. At each visit, testing was performed both pre- and post-bronchodilator (BD) administration.

Time frame:
Single-Dose Week 5/Intravenous Week 1, and Repeat-Dose Weeks 1, 4, and 9
Reported as:
Mean · litres
Change From Baseline in Forced Vital Capacity (FVC)
litresCohort 1Cohort 2
Pre-BD - IV Week 1-0.149 ± 0.2432-0.156 ± 0.2787
Pre-BD - RD Week 1-0.025 ± 0.27160.310 ± 0.3024
Pre-BD - RD Week 40.128 ± 0.4371-0.296 ± 0.2666
Pre-BD - RD Week 90.114 ± 0.2086-0.185 ± 0.3247
Post-BD - IV Week 1-0.059 ± 0.1377-0.120 ± 0.2017
Post-BD - RD Week 1-0.003 ± 0.2085-0.327 ± 0.3813
Post-BD - RD Week 40.172 ± 0.3729-0.322 ± 0.4258
Post-BD - RD Week 90.114 ± 0.2185-0.143 ± 0.3649
PrimaryNumber of Participants With Any Adverse Events Associated With Abnormalities in Laboratory Parameters (Chemistry, Hematology, Urinalysis)

Out of the normal range laboratory results judged by the Investigator as clinically significant in the context of the participant's medical history were considered adverse events.

Time frame:
Up to 668 days
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Events Associated With Abnormalities in Laboratory Parameters (Chemistry, Hematology, Urinalysis)
ParticipantsCohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)
Number of Participants With Any Adverse Events Associated With Abnormalities in Laboratory Parameters (Chemistry, Hematology, Urinalysis)000011
PrimaryImmunogenicity: Number of Participants With Alpha1-PI Antibodies

Immunogenicity testing was performed using validated assays in a multi-tiered approach.

Time frame:
Treatment Period 1- Single-Dose Week 1; Treatment Period 2- Repeat-Dose Weeks 1 and 9
Reported as:
Count of participants · Participants
Immunogenicity: Number of Participants With Alpha1-PI Antibodies
ParticipantsCohort 1Cohort 2
Immunogenicity: Number of Participants With Alpha1-PI Antibodies00

Adverse events

Collected over Up to 668 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)0/9 (0%)0/9 (0%)5/9 (55.6%)
Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)0/8 (0%)0/8 (0%)7/8 (87.5%)
Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)0/6 (0%)1/6 (16.7%)3/6 (50%)
Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)0/8 (0%)0/8 (0%)3/8 (37.5%)
Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)0/8 (0%)2/8 (25%)7/8 (87.5%)
Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)0/7 (0%)1/7 (14.3%)4/7 (57.1%)
Most frequent serious events
Most frequent serious events
EventCohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/90/81/60/81/80/7
Acute promyelocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/90/80/60/80/81/7
Chronic respiratory failureRespiratory, thoracic and mediastinal disorders0/90/80/60/81/80/7
Hip fractureInjury, poisoning and procedural complications0/90/80/60/81/80/7
Most frequent other events
Showing 10 of 62
Most frequent other events
EventCohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/92/81/60/82/81/7
WheezingRespiratory, thoracic and mediastinal disorders0/92/80/60/80/80/7
COVID-19Infections and infestations0/92/80/60/80/80/7
Infusion site painGeneral disorders0/90/80/62/80/80/7
Infusion site erythemaGeneral disorders2/90/80/60/80/80/7
Infusion site reactionGeneral disorders0/90/81/60/80/80/7
Vaginal infectionInfections and infestations0/90/81/60/80/80/7
NauseaGastrointestinal disorders0/91/80/60/81/81/7
Infusion site bruisingGeneral disorders0/90/80/60/80/81/7
Infusion site dermatitisGeneral disorders0/90/80/60/80/81/7

Baseline characteristics

The Safety Population included all participants who received any dose of study treatment (Alpha-1 15% or Liquid Alpha1-PI) and were used for all analyses and summaries other than those for PK.

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Total
Mean63.8 ± 5.7469.1 ± 7.5966.3 ± 7.02
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female5611
Male426
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White9817
More than one race000
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Total
Hispanic or Latino202
Not Hispanic or Latino7815
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1Cohort 2Total
United States9817
08

Study locations

5 sites
  • GC2008 Study Site 107
    Los Angeles, California 90025, United States
  • GC2008 Study Site 108
    Gainesville, Florida 32610, United States
  • GC2008 Study Site 102
    Miami, Florida 33136, United States
  • GC2008 Study Site 103
    Cleveland, Ohio 44195, United States
  • GC2008 Study Site 101
    Charleston, South Carolina 29425, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2021 to primary completion in Aug 2025, 43 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Start moved once since we started tracking on Sep 25, 2026: Aug 2021 → Dec 2021, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2021
First posted
Jan 25, 2021
StartActual
Dec 16, 2021was Aug 2021
Primary completionActual
Aug 1, 2025
CompletionActual
Aug 1, 2025
Results first posted
Oct 8, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 8, 2026
Sites
5 sites added, 5 sites removed
Show 5 added (5 United States)
  • GC2008 Study Site 107 · Los Angeles, United States
  • GC2008 Study Site 108 · Gainesville, United States
  • GC2008 Study Site 102 · Miami, United States
  • GC2008 Study Site 103 · Cleveland, United States
  • GC2008 Study Site 101 · Charleston, United States
Show 5 removed
  • UCLA Medical Center · Los Angeles, United States
  • University of Florida · Gainesville, United States
  • University of Miami · Miami, United States
  • Cleveland Clinic · Cleveland, United States
  • Medical University of South Carolina - Children's Hospital · Charleston, United States
Oct 8, 2026
Start date
Aug 13, 2021→Dec 16, 2021
Oct 8, 2026
Eligibility
1 criterion edited, 2 added
What changed in the criteria
  • AddedMain Inclusion Criteria:
  • EditedHave a documented pre-Alpha1-Proteinase Inhibitor (PI) augmentation therapy serum alpha-1 antitrypsin (AAT) level <11 micrometermicromolar (μM) (80 milligrams per decilitre (mg/dL) if measured by radial immunodiffusion or 50 mg/dL if measured by nephelometry).
  • AddedMain Exclusion Criteria:
Oct 8, 2026
Primary outcomes
7 edited, 4 description edited
What changed in the outcomes
  • EditedNumber of Participants With Treatment Emergent Adverse Events (AEsTEAEs)Time frame: Up to 668 days
  • EditedNumber of Participants With Infusion Site Reactions (ISRs)Time frame: Up to 668 days
  • EditedNumber of Participants With AEs and SAEsAny TEAE Leading to DiscontinuationStudy WithdrawalTime frame: Up to 668 days
  • EditedNumber of Participants With Clinically SignificantAny Adverse Events Associated With Abnormalities in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate, and Temperature)Time frame: Up to 668 days
  • EditedChange fromFrom Baseline in Forced Expiratory Volume in 1 Second (FEV1)Time frame: Up to 668 days → Single-Dose Week 5/Intravenous Week 1, and Repeat-Dose Weeks 1, 4, and 9
  • EditedChange fromFrom Baseline in Forced Vital Capacity (FVC)Time frame: Up to 668 days → Single-Dose Week 5/Intravenous Week 1, and Repeat-Dose Weeks 1, 4, and 9
  • EditedNumber of Participants With Clinically SignificantAny Adverse Events Associated With Abnormalities in Laboratory Parameters (Chemistry, Hematology, Urinalysis)Time frame: Up to 668 days
  • DescriptionImmunogenicity: Number of Participants With Alpha1-PI Antibodies: how it is measured was reworded
  • DescriptionNumber of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations: how it is measured was reworded
  • DescriptionNumber of Participants With Serious Adverse Events (SAEs): how it is measured was reworded
  • DescriptionNumber of Participants With Suspected Adverse Drug Reactions (ADRs): how it is measured was reworded
Oct 8, 2026
Documents
Show all 1 update
  1. Oct 8, 2026
    Results posted
    5 sites added, 5 sites removed
    Show 5 added (5 United States)
    • GC2008 Study Site 107 · Los Angeles, United States
    • GC2008 Study Site 108 · Gainesville, United States
    • GC2008 Study Site 102 · Miami, United States
    • GC2008 Study Site 103 · Cleveland, United States
    • GC2008 Study Site 101 · Charleston, United States
    Show 5 removed
    • UCLA Medical Center · Los Angeles, United States
    • University of Florida · Gainesville, United States
    • University of Miami · Miami, United States
    • Cleveland Clinic · Cleveland, United States
    • Medical University of South Carolina - Children's Hospital · Charleston, United States
    Start date Aug 13, 2021→Dec 16, 2021
    Eligibility 1 criterion edited, 2 added
    What changed in the criteria
    • AddedMain Inclusion Criteria:
    • EditedHave a documented pre-Alpha1-Proteinase Inhibitor (PI) augmentation therapy serum alpha-1 antitrypsin (AAT) level <11 micrometermicromolar (μM) (80 milligrams per decilitre (mg/dL) if measured by radial immunodiffusion or 50 mg/dL if measured by nephelometry).
    • AddedMain Exclusion Criteria:
    Primary outcomes 7 edited, 4 description edited
    What changed in the outcomes
    • EditedNumber of Participants With Treatment Emergent Adverse Events (AEsTEAEs)Time frame: Up to 668 days
    • EditedNumber of Participants With Infusion Site Reactions (ISRs)Time frame: Up to 668 days
    • EditedNumber of Participants With AEs and SAEsAny TEAE Leading to DiscontinuationStudy WithdrawalTime frame: Up to 668 days
    • EditedNumber of Participants With Clinically SignificantAny Adverse Events Associated With Abnormalities in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate, and Temperature)Time frame: Up to 668 days
    • EditedChange fromFrom Baseline in Forced Expiratory Volume in 1 Second (FEV1)Time frame: Up to 668 days → Single-Dose Week 5/Intravenous Week 1, and Repeat-Dose Weeks 1, 4, and 9
    • EditedChange fromFrom Baseline in Forced Vital Capacity (FVC)Time frame: Up to 668 days → Single-Dose Week 5/Intravenous Week 1, and Repeat-Dose Weeks 1, 4, and 9
    • EditedNumber of Participants With Clinically SignificantAny Adverse Events Associated With Abnormalities in Laboratory Parameters (Chemistry, Hematology, Urinalysis)Time frame: Up to 668 days
    • DescriptionImmunogenicity: Number of Participants With Alpha1-PI Antibodies: how it is measured was reworded
    • DescriptionNumber of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations: how it is measured was reworded
    • DescriptionNumber of Participants With Serious Adverse Events (SAEs): how it is measured was reworded
    • DescriptionNumber of Participants With Suspected Adverse Drug Reactions (ADRs): how it is measured was reworded
    + 3 other changes: index terms, verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04722887
Responsible party
Sponsor
First posted
Jan 25, 2021
Start date
Dec 16, 2021
Primary completion
Aug 1, 2025
Completion
Aug 1, 2025
Results posted
Oct 8, 2026
Last update
Oct 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Homo sapiens whole

Start the discussion